Novel therapeutics in the treatment of bladder cancer

Current Opinion in Urology

Volumn 14, Issue 5, 2004, Pages 287-293

  Shah, Jay B ^a   McKiernan, James M ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Bladder cancer; Chemoenhancement; Chemotherapy; Immunotherapy; Intravesical therapy; Novel therapeutics

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CISPLATIN; CLUSTERIN; DNA VACCINE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; METHOTREXATE; MICROSPHERE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PHOTOSENSITIZING AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE; TRASTUZUMAB; VALRUBICIN; VINBLASTINE;

BLADDER CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYSTECTOMY; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; METASTASIS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; TH1 CELL; TUMOR GROWTH; TUMOR VOLUME;

HUMANS; IMMUNOTHERAPY; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 4344593223     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200409000-00007     Document Type: Review

References (36)

1. National Cancer Institute. National Cancer Institute Surveillance, Epidemiology, and End Results Cancer Statistics Review Internet site. http://seer. cancer.gov/csr/1975_2000/results_merged/sect_26_urinary_bladder. pdf. [Accessed 29 May 2004].
2. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
4. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166:1300-1305.
5. Belldegrun AS, Franklin JR, O'Donnell MA, et al. Superficial bladder cancer: the role of interferon-α. J Urol 1998; 159:1793-1801.
6. Kalble T, Beer M, Mendoza E, et al. BCG vs. interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 1994; 33:133-137.
7. O'Donnell MA, Luo Y, Hunter SE, et al. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 2004; 171:1330-1335. Interesting study of the therapeutic effects of interleukin-12 in a murine bladder cancer model.
8. Lee C, Chang S, Hsieh D, Yu D. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol 2004; 171:1343-1347. A comprehensive analysis of the possible role for DNA vaccines in the treatment of bladder cancer.
9. Dalbagni G, Mazumdar M, Russo P, et al. Phase II trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder [abstract]. J Urol 2004; 171(4S):72-A274. First trial showing efficacy of gemcitabine as an intravesical instillation agent.
10. Leakakos T, Cheng J, Lawson G, et al. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003; 51:445-450. A pilot study in a noncancer model showing the potential for magnetically targeted carriers to be used intravesically.
11. Nativ O, Aronson M, Medalia O, et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 1997; 70:297-301.
12. Le Visage C, Rioux-Leclercq N, Haller M, et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 2004; 171:1324-1329. An innovative idea aimed at improving the efficiency of intravesical paclitaxel delivery. May also have applicability to other intravesical agents in the future.
13. Miyake H, Eto H, Hara I, et al. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer koTCC-1 cells. J Urol 2004; 171:2477-2481. A well-designed and thoroughly executed study looking at the utility of antisense oligodeoxynucleotides to inhibit clusterin expression and potentiate gemcitabine cytotoxicity.
14. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res 2000; 60:2547-2554.
15. Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360-367.
16. Fuessel S, Kueppers B, Ning S, et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004; 171:2471-2476. Early in-vitro analysis of survivin as another potential target for antisense oligodeoxynucleotides.
17. Gakiopoulou H, Nakopoulou L, Siatelis A, et al. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003; 9:5573-5581. Observational study correlating levels of tissue inhibitor of metalloproteinase-2 expression with clinicopathological parameters in patients with bladder cancer.
18. Koga F, Kageyama Y, Kawakami S, et al. Prognostic significance of endothelial Per-Arnt-Sim domain protein 1/hypoxia-inducible factor-2α expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 2004; 171:1080-1084. Quantitative study of endothelial Per-Arnt-Sim domain protein 1 (EPAS-1) levels in human bladder cancer tissue sections to assess prognostic value of EPAS1 expression.
19. Malkowicz SB. Management of superficial bladder cancer. In: Walsh P, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology. Vol 4, 8th ed. New York: Saunders; 2002. pp. 2785-2802.
20. French AJ, Datta SN, Allman R, Matthews PN. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. BJU Int 2004; 93:156-161. Interesting in-vitro analysis of the ability of mitomycin C to increase efficacy of photodynamic therapy, even in mitomycin-resistant cell lines.
21. Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C. Adjuvant intravesical mitoxantrone versus recombinant interferon-α after transurethral resection of superficial bladder cancer: a randomized prospective study. Urol Int 2004; 72:284-291. Clinical trial comparing two compounds not commonly used as single agents in management of superficial bladder cancer.
22. Smith JA, Crawford ED, Paradelo JC, et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone; a phase III intergroup study. J Urol 1997; 157:805-807.
23. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-464.
24. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152:81-84.
25. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153:47-52.
26. Freiha F, Reese J, Torti FM, et al. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine, and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155:495-499.
27. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64:2448-2458.
28. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003; 349:859-866. Long-awaited results of landmark Southwest Oncology Group study showing beneficial effect of neoadjuvant chemotherapy in patients undergoing cystectomy. The authors give a meaningful comparison of their results and the results of other studies on this topic.
29. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-2569.
30. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
31. Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003; 170:2000-2003. In-vitro and in-vivo exploration of the possible mechanism by which endostatin may inhibit bladder tumor growth.
32. Kikuchi E, Menendez S, Ohori M, et al. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res 2004; 10:1835-1842. Pilot study examining lentivirus as potential gene therapy vector for delivery of endostatin to bladder cancer cells.
33. Inoue K, Chikazawa M, Fukata S, et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 2002; 8:2389-2398.
34. Inoue K, Chikazawa M, Fukata S, et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003; 9:886-899. Novel in-vitro and in-vivo examination of docetaxel plus TNP-470 to determine if different anti-tumor mechanisms are synergistic.
35. Karashima T, Sweeney P, Kamat A, et al. Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003; 9:2786-2797.
36. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40:56-63. Interesting study of HER2/neu levels in human bladder cancer suggesting that anti-HER2 therapy may not be efficacious in treatment of this disease entity.